Effect of dexmedetomidine as an adjuvant in brachial plexus block on EC50 for propofol target-controlled infusion at loss of consciousness

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009752

Enrollment

Unknown

Registered

2016-11-06

Start date

2016-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elective upper limb surgery

Interventions

R group:0.5% ropivacaine alone

RD1 group:0.5% ropivacaine with 0.5 ug/kg dexmedetomidine

RD2 group:0.5% ropivacaine with 1 ug/kg dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA grade I-II patients, 18-65 years old, scheduled for elective upper limb orthopaedic surgery under brachial plexus block.

Exclusion criteria

Exclusion criteria: Patients with a history of hypertension, cerebrovascular disease, peripheral neuropathy, hepatic or renal disorders, psychiatric disease, bradycardia or coagulopathies will be excluded.

Design outcomes

Primary

Measure	Time frame
effect-site propofol concentration;BIS;	—

Secondary

Measure	Time frame
analgesia effect;recovery time;	—

Countries

China

Contacts

Public ContactBoxiang Du

The Second Affiliated Hospital of Nantong University

boxiang_du@aliyun.com+86 15262839991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026